Prognostic Factors in Patients With Colorectal Cancer at Hospital Universiti Sains Malaysia  by Ghazali, Anis Kausar et al.
ASIAN JOURNAL OF SURGERY VOL 33 • NO 3 • JULY 2010 127
© 2010 Elsevier. All rights reserved.
Original Article
Prognostic Factors in Patients With Colorectal Cancer
at Hospital Universiti Sains Malaysia
Anis Kausar Ghazali,1 Kamarul Imran Musa,2 Nyi Nyi Naing1 and Zainal Mahmood,3
1Unit of Biostatistics and Research Methodology, 2Department of Community Medicine and 
3Department of Surgery, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
OBJECTIVE: To determine the 5-year survival rate and prognostic factors for survival in patients with
colorectal cancer treated at the Surgical Unit, Hospital Universiti Sains Malaysia (HUSM), Kelantan,
Malaysia.
METHODS: We retrospectively reviewed the records of 115 patients treated in HUSM from 1996 to 2005.
Data of variables considered as prognostic factors were obtained from the records. Simple and multiple
Cox proportional hazard regression using the stepwise method were used to model the prognostic 
factors for survival.
RESULTS: We found that the significant prognostic factors were liver metastases [adjusted hazard ratio
(HR): 3.75; 95% confidence interval (CI): 1.95–7.22], Dukes C stage (adjusted HR: 4.65; 95% CI: 2.37–9.11),
Dukes D stage (adjusted HR: 6.71; 95% CI: 2.92–15.48) and non-surgical treatment (adjusted HR: 3.75;
95% CI: 1.26–11.21).
CONCLUSION: Colorectal patients treated at HUSM with Dukes C staging, presence of liver metastases
and received treatment with both chemotherapy and radiotherapy are at the greatest risk of death from
colorectal cancer. [Asian J Surg 2010;33(3):127–33]
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Introduction
Colorectal cancer is the third most common cancer
worldwide after lung and breast cancer; it accounts for an
estimated more than one million new cancer cases and
over 590,000 cancer deaths per year, which is almost 10%
of all cancer deaths.1,2 Asian countries, including China,
Japan, South Korea and Singapore, have experienced 
a 2–4-fold increase in the incidence of colorectal cancer
during the past few decades.3 It was the most common
cancer in Singapore, while in Malaysia, it was the third
most common cancer among males and females with
prevalences of 7.6% and 6.0%, respectively. On the other
hand, rectal cancer was the fifth most common cancer
with prevalences of 6.6% in males and 4.1% in females.4,5
Multiple prognostic factors that affect the survival of
patients with colorectal cancer have been identified, e.g.
Dukes stage, number of lymph nodes involved, lymph
node metastases, preoperative carcinoembryonic antigen
(CEA) level and tumour location.6–9 The best estimate of
prognosis in colorectal cancer is related to the anatomic
extent of disease determined by the pathological exami-
nation of the resected specimen.10 However, the accurate
determination of prognostic factors for colorectal cancer
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remains a problem and further studies are needed to
determine the role of clinical and pathological factors in
colorectal cancer especially for local data in Malaysia.6
Thus we performed a study to determine the pattern
of survival and prognostic factors for patients with colo-
rectal cancer treated at the Surgical Unit, Hospital
Universiti Sains Malaysia (HUSM), a large tertiary hospi-
tal in Malaysia. To the best of our knowledge, there has
been no published localised study on prognostic factors
for colorectal cancer, and identification of prognostic 
factors can help in the management of patients and in
planning better intervention and prevention programs
for such patients, particularly in Malaysia.
Patients and methods
This was a retrospective record review study, in which we
obtained, from the HUSM record office, the medical
records of patients diagnosed with colorectal cancer and
treated in HUSM from 1996 until the end of 2005. The
reference population for this study comprised all patients
with colorectal cancer admitted to HUSM, while the source
population was all patients diagnosed with colorectal
cancer and treated in HUSM over 10 years (1996–2005).
The inclusion criteria were patients with confirmed
diagnosis of colorectal cancer based on histopathological
findings as defined by the International Classification of
Disease Clinical Modification 9th edition ICD-9-CM code
(153.0–154.1) for cases pre-2000 and ICD-10 code (C.18–
C.20) for cases post-2000, and patients who had a history of
being treated at least once at HUSM.11 We excluded medical
records with more than 30% incomplete information.
We calculated the sample size using the Power and
Sample Size Calculation software program.12 The level of
significance, α and the power, 1 − β, of the study were set
at 0.05 (two-sided) and 0.80, respectively. The median sur-
vival time for patients who were on usual treatment and
the ratio of control to experimental patients were obtained
from the literature. The detectable hazard ratio was de-
cided by the researcher and the senior surgeons who were
managing the colorectal cancer patients in HUSM. The
accrual patient recruitment time was 120 months. Ten
percent of the final figure was added for the anticipation
of some missing values and nonresponse cases, which
made the final sample size for this study 140 patients.
The variables of interest were sociodemographic data
such as age, race, sex, type of occupation and smoking 
status. The age of the patients was defined as age in years
at the final diagnosis. This was performed by calculating
the difference between the year of final diagnosis and the
year the patient was born. The date of the final diagnosis
was obtained from the histopathological examination
report. The patients’ race was categorized either as Malay
or non-Malay, because patients in this part of Malaysia
were mainly from the Malay ethnic group. Smokers were
defined as patients who were smokers prior to the study
recruitment phase irrespective of the amount of cigarettes
smoked. Ex-smokers were those who had history of smok-
ing but had already ceased smoking before they were diag-
nosed with colorectal cancer. Nonsmokers were those
who had never smoked in their lifetime.
The clinical characteristics of interest were tumour
site, stage at diagnosis, presence of metastases, per rectal
bleeding, and CEA level. The tumour site was categorized
according to the tumour location identified at the time 
of diagnosis. They were categorized into colon, rectum
and rectosigmoid. Cancer of the colon was defined as 
a tumour in the ascending colon, descending colon, trans-
verse colon, hepatic flexure, splenic flexure or transverse
colon.
We used Dukes staging to classify the various stages of
the colorectal cancer. As there was no patient in the
Dukes A group in our study, the staging was thus classi-
fied into three categories only; Dukes B, Dukes C and
Dukes D. The presence of metastases was categorized irre-
spective of when metastases had occurred. Only liver
metastases had been chosen for study as the prognostic
factor since it is the most common site of metastases in
colorectal cancer.13 Per rectal bleeding was determined
according to the initial symptoms reported in the medical
records regardless of its duration since it was rarely avail-
able in the patients’ medical record. We used the preoper-
ative assessment of CEA level where the CEA level was
divided into ≤ 5 ng/mL and > 5 ng/mL and a CEA value of
> 5 ng/mL was considered abnormal.8 For comorbidities,
we categorized them into three categories: without comor-
bidity, single comorbidity and two or more comorbidities.
There were four treatment modalities: surgery, surgery
with chemotherapy or radiotherapy, surgery followed by
chemotherapy and radiotherapy, and chemotherapy and/
or radiotherapy (nonsurgical treatment) alone.
The patients’ survival status was classified into three
categories: dead, alive or loss to follow-up. If the patient
died, the date and cause of death were recorded. The cause
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of death was categorized into death from colorectal can-
cer or death from other causes. The exact date and cause
of death were obtained from the medical records. If 
the survival status was not available in the medical record,
we acquired it by contacting the patients themselves or
their relatives if the patients were not contactable. This
was possible because the medical records contained the
phone numbers and the addresses of the patients and
their relatives.
Ethical clearance was obtained from the Research and
Ethics Committee of HUSM (Reference number: USMKK/
PPSP/JEPem, USM [194.4(3.3)]), Malaysia.
We used Stata/SE version 9.2 (StataCorp. College
Station, TX, USA) for data entry and data analysis. The sim-
ple Cox regression analysis was conducted for all inde-
pendent variables or predictors to screen the variables at
the univariate level. The predictors were considered impor-
tant if the p value was lower than 0.25.14 The multiple Cox
proportional hazard regression model was applied to
model the prognostic factors. We used the full stepwise
selection method for variable selection, and the p value of
lower than 0.05 was chosen for variable entry, while the 
p value of greater than 0.1 was used for variable removal.
We tested two-way interaction terms between the 
variables in the preliminary main analysis, checked the
presence of serious multicollinearity, examined the pro-
portional hazards assumption and measured the good-
ness of fit and the diagnostic statistics for model
adequacy. For all the predictor categorical variables, the
assumption of proportionality was analyzed by inspec-
tion of the log cumulative hazard curve plotted against
log time, also known as the log minus log plot. Addition-
ally, we inspected the scaled Schoenfeld partial residual
plot and evaluated the proportionality significance using
the scaled Schoenfeld for each predictor variable and the
Schoenfeld for global test. Martingale residuals were
checked to determine the functional form of covariates 
to be included in the model and to assess the model’s lack
of fit. Cox Snell residuals were checked for overall model
fitness. Deviance residual was assessed to examine the
model accuracy and identifying outliers. The cut-off point
for residual plot deviance was ± 4. The df-beta residual
plot was examined to identify influential observations.
The final model was presented with the adjusted hazard
ratio (HR) with 95% confidence interval (CI) and its cor-
responding p value. The level of significance was set at
0.05 in two-tailed fashion.
Results
Data from 115 patients with colorectal cancer treated at
the Surgical Unit, HUSM, were analyzed, and the results
showed that the mean age of the colorectal patients was
55.7 years, 62.6% (n = 72) were male and 76.5% (n = 88) were
from the Malay ethnic group. The 5-year survival rates along
with their 95% CI, according to the sociodemographic and
clinical profiles, are shown in Table 1. This shows that those
patients who were older than 70 years, who were male, who
had cancer of the colon classified as Duke B and who had
two or more comorbidities have the highest survival rate.
In Table 2, we show the result from the simple Cox
regression analysis. The predictor variables examined were
age, sex, race, working status, smoking status, per rectal
bleeding, liver metastasis, site of tumour, Dukes staging,
preoperative CEA level and treatment modalities. The sig-
nificant (p values less than 0.05) crude or unadjusted
Table 1. Five-year survival rate from Kaplan-Meier estimates
(n = 115)
Survival 95% Confidence interval
Variables
rate (%) Lower limit Upper limit
Age group (yr)
16.0–49.9 30.3 15.8 46.1
50.0–69.9 31.4 18.1 45.5
≥ 70.0 53.3 26.3 74.8
Sex
Male 38.4 22.5 54.1
Female 32.3 20.6 44.5
Race
Malay 28.4 18.3 39.4
Non-Malay 52.9 29.7 71.5
Site of tumour
Colon 43.9 29.1 57.7
Rectum 22.8 8.7 40.9
Rectosigmoid 29.3 11.1 50.5
Dukes staging*
Duke B 68.4 50.3 81.1
Duke C 12.1 2.9 14.6
Comorbidities
None 27.4 16.4 39.5
Single 37.4 12.1 63.3
Two or more 48.3 26.6 67.1
*Duke D cannot be determined because of the small sample size.
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prognostic variables were age, race, Dukes staging, liver
metastases, preoperative CEA level and treatment modal-
ities. The potential predictor variables in the simple Cox
regression were those with p values of less than 0.25 and/or
possessed clinical or biological importance. They were fur-
ther analyzed in the multiple Cox regression analysis.
We used multiple Cox regression, also known as 
the proportional hazards model, to model the important
Table 2. Prognostic factors in simple Cox regression analysis*
Variables Mean (SD) or n (%) Crude HR (95% CI) LR p†
Age (yr) 55.7 (14.4) 0.98 (0.97–0.99) 4.04 0.044
Age group
16–49 40 (34.8) 1.00 – –
50–69 60 (52.2) 0.82 (0.50–1.35) −0.77 0.440‡
≥ 70 15 (13.0) 0.63 (0.28–1.38) −1.16 0.245‡
Sex
Female 43 (37.4) 1.00 – –
Male 72 (62.6) 1.08 (0.66–1.76) 0.10 0.75
Race
Non-Malay 27 (23.5) 1.00 – –
Malay 88 (76.5) 2.26 (1.19–4.30) 7.38 0.006
Per rectal bleeding
No 58 (50.4) 1.00 – –
Yes 57 (49.6) 1.28 (0.81–2.05) 1.10 0.294
Dukes staging
B 50 (43.5) 1.00 – –
C 38 (33.0) 5.19 (2.76–9.79) 5.10§ < 0.001‡
D 27 (23.5) 15.30 (7.57–30.9) 7.60§ < 0.001‡
Liver metastasis status
No 70 (60.9) 1.00 – –
Yes 45 (39.1) 5.74 (3.46–9.51) 46.1 < 0.001
Site of tumour
Colon 48 (41.7) 1.00 – –
Rectum 41 (35.7) 1.60 (0.93–2.75) 1.72§ 0.086‡
Rectosigmoid 26 (22.6) 1.49 (0.80–2.79) 1.25§ 0.211‡
Preoperative CEA level (ng/mL)
≤ 5 45 (39.1) 1.00 – –
> 5 70 (60.9) 3.39 (1.96–5.89) 22.3 < 0.001
Comorbidities
None 68 (59.1) 1.00 – –
Single 22 (19.1) 0.67 −1.25§ 0.210‡
Two or more 25 (21.7) 0.54 −1.90§ 0.057‡
Treatment modalities
Surgery + chemotherapy + radiotherapy 20 (17.4) 1.00
Surgery + chemotherapy or radiotherapy 59 (51.3) 0.97 (0.50–1.90) −0.08§ 0.938‡
Surgery alone 31 (27.0) 2.23 (1.10–4.51) 2.24§ 0.025‡
Chemotherapy and/or radiotherapy 5 (4.3) 5.60 (1.92–16.31) 3.16§ 0.002‡
*The fourth column shows the values of the Likelihood ratio (LR) test statistic unless mentioned specifically as Z value. The last column con-
tains the corresponding p value of the LR test statistic or Wald test statistic; †p for LR statistic; ‡p for Wald statistic; §Z value for Wald statis-
tic. HR = hazard ratio; CI = confidence interval; CEA = carcinoembryonic antigen.
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predictors for survival in the patients. The significant
prognostic factors from the final model of multiple Cox
regression analysis were liver metastasis status, Dukes stag-
ing and treatment modalities and are shown in Table 3.
We can interpret Table 3 as follows: The patients with liver
metastases have almost four times the risk of dying from
colon cancer and the risk can be in the range of two to
seven times (95% CI) when compared with those without
metastases. In addition, patients in Duke D or Duke C
stages have, respectively, a 6-fold and 5-fold greater risk
of dying than patients with Duke B stage. While those
patients who received both chemotherapy and radiother-
apy were at the greatest risk of dying from colon cancer
compared to the other treatment modalities.
Discussion
Colon cancer is a major cancer in humans and one of the
cancers with the most considerable mortality. Various
studies have tried to determine the factors associated with
death from colon cancer; however, findings were incon-
sistent and inconclusive. In this study, we analyzed a total
of 115 patients with colon cancer, diagnosed and treated
at the HUSM Surgical Unit, to determine the important
predictors for survival status in our local setting.
The overall 5-year survival rate for colorectal cancer
patients in this study (34.3%) was lower compared with the
overall 5-year survival rate in developed countries such as
Australia, with overall survival rates of 50% or more. How-
ever, the result is similar to a study in Bombay, India, where
the overall 5-year survival rates for colon and rectal cancer
were 31.2%.15,16 At our centre, the older patients had a bet-
ter 5-year survival rate (53.3%) compared with the younger
age group (30.3%) in this study, similar to a study in
Korea.6 Of the 88 Malay patients in this study, 60 (68.2%)
patients had died, compared with 11 (40.7%) patients from
other races, resulting in a 5-year survival rate of 28.4% for
Malay patients and 52.9% for non-Malays.
We found that the Dukes staging was the strongest
prognostic factor in both univariate and multivariate
analysis. This result was found to be consistent with those
of other studies.6,17,18 The highest HR was found to be in
Dukes D patients. Nonsurgical treatment modalities
(chemotherapy and/or radiotherapy) also significantly
influenced the survival of patients in this study but con-
tradicted the findings from Yeole et al16 in his study in
Bombay. In that study, patients who had not undergone
treatment (39.3% of cases) were included, which is in con-
trast with our study where we excluded those patients.
However, the small number of patients (n = 5) in the non-
surgical treated group yielded a wide CI for the HR
(adjusted HR: 3.75; 95% CI: 1.26–11.21).
Liver metastases status was a significant prognostic
factor in this study similar to the findings of another
study in Japan.15 Patients with liver metastasis had almost
four times the risk of death in comparison to those without
Table 3. Final model of prognostic factors of 115 patients with colorectal cancer using the multiple Cox proportional hazards regres-
sion model
Variables Adjusted HR (95% CI) p*
Liver metastases
No 1.00 –
Yes 3.75 (1.95–7.22) < 0.001
Dukes staging
B 1.00 –
C 4.65 (2.37–9.11) < 0.001
D 6.71 (2.92–15.48) < 0.001
Treatment modalities
Surgery + chemotherapy + radiotherapy 1.00 0.212
Surgery + chemotherapy or surgery + radiotherapy 0.64 (0.32–1.28) 0.113
Surgery alone 1.81 (0.87–3.77) 0.018
Chemotherapy + radiotherapy 3.75 (1.26–11.21)
*p value for Wald statistics. HR = hazard ratio; CI = confidence interval.
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liver metastases. Age at diagnosis had no significant influ-
ence on the risk of death in patients with colorectal can-
cer and is consistent with other studies.6,8,15,19–21 However,
a few studies reported that age was a significant predictor
for death.17,18
We could not establish that tumour site was an impor-
tant predictor for survival status even though Wrigley 
et al (2002) showed that a tumour in the rectum was a sig-
nificant predictor for survival status in their multivari-
able method.17 Per rectal bleeding was a prognostic factor
in another study but not in our study.22 However, that
study included other symptoms such as anaemia, abdom-
inal pain, diarrhoea, and loss of weight as well as other
confounders. The combination of more symptoms to be
controlled might have given different results compared
with our study.
Comorbidities were not important prognostic factors;
this was a similar finding to the study by Wrigley et al.17
The ratio of patients in the three comorbidity groups for
both studies was almost the same, which may have been
the reason for this similarity. In addition, instead of spec-
ifying the type of comorbidity, both studies chose to sim-
ply score the number of comorbidities that the patients
had regardless of the type and level of severity of the
comorbidity.
In this study, the preoperative CEA level was only sig-
nificantly related to survival prognosis in univariate
analysis but was not an independent prognostic factor in
multivariate analysis. This finding was similar to the stud-
ies by Tominaga et al (1996),23 Hamm and Crips (1998),24
Schwandner et al (2007),25 but not to several other studies
such as those of Park et al (1999), Wang et al (2000) and
Yun et al (2007).6,8,21 In one study, however, the preopera-
tive CEA level was reported to be a significant prognostic
factor only in the late stage of the cancer.26
Despite some limitations, the strength of this study
can be seen from the sample size (n = 115), which was close
to the calculated sample size (127), with average post hoc
power of 76%.
In conclusion, Dukes staging, status of liver metas-
tases and type of treatment are the important indepen-
dent predictors for survival in patients with colorectal
cancer, diagnosed and treated at the Surgical Unit,
HUSM, Malaysia. Those with Dukes C staging, with the
presence of liver metastases and who are treated with
both chemotherapy and radiotherapy are at the greatest
risk of death from colorectal cancer.
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